About Organigram Holdings

OrganiGram Holdings Inc., through its wholly-owned subsidiaries, produces cannabis and cannabis-derived products in Canada regulated by Health Canada under the Cannabis Act and the Cannabis Regulations. The company is authorized for the wholesale shipping of cannabis plant cuttings, dried flower, blends, pre-rolls and cannabis derivative-based products to approved retailers and wholesalers for adult-use recreational cannabis under the individual provincial and territorial regulations as per the Cannabis Act (the Cannabis Act (Canada) and the Cannabis Regulations (Canada) (together, the ‘Cannabis Act’)). The company is also authorized to distribute cannabis for medical use. In 2022, the company made a strategic decision to shift its medical distribution fulfillment approach from direct shipment to patients from the company to fulfillment via Medical Cannabis by Shopper’s Drug Mart. The company continues to be committed to medical patients via its Shopper's Drug Mart relationship and will also continue to bring new innovations to this channel. The company conducts its operations at its facilities located in Moncton, New Brunswick, Winnipeg, Manitoba and Lac-Supérieur, Quebec. The company has expanded its main facility in Moncton over time to create additional production capabilities by strategically acquiring land and buildings adjacent to the main facility (together, the ‘Moncton Campus’), including to add capacity for the manufacture of derivative product forms. In March 2021, the company formed a Product Development Collaboration (PDC) with British American Tobacco P.L.C. (BAT), a multi-category consumer goods business, and established a ‘Centre of Excellence’ (the CoE) to focus on the next generation of cannabis products with an initial focus on cannabidiol (CBD). The CoE is established at the company's Moncton Campus, which holds the Health Canada licenses required to conduct research and development activities with cannabis products. Under the terms of the Product Development Collaboration (PDC) Agreement, both the company and BAT have access to certain of each other’s intellectual property (IP) and, subject to certain limitations, have the right to independently, globally commercialize the products, technologies and IP created by the CoE pursuant to the PDC Agreement. During April 2021, the company expanded its manufacturing and production footprint with the acquisition of The Edibles and Infusions Corporation (EIC), located in Winnipeg, Manitoba. The Winnipeg Facility holds a research license and standard sale and processing license under the Cannabis Act. As a wholly-owned subsidiary, EIC has enabled the company to penetrate a new product category and gain access to its expertise in the confectionary space. The Winnipeg Facility also provides the company with a share of the cannabis infused gummies market and other derivative products. The company has additional cannabis production capacity at its wholly-owned subsidiary, Laurentian, located in Lac-Supérieur, Quebec, acquired in December 2021. The Lac-Supérieur Facility has a cultivation focus on artisanal craft flower and on the production of hash, a cannabis derivative. The Lac-Supérieur Facility provides the company with a foothold in the important Quebec market, and also adds to the company's premium product portfolio, providing further opportunities for margin expansion. The facility holds a standard processing and cultivation license under the Cannabis Act. Strategy The company’s strategy is to leverage its broad brand and product portfolio and culture of innovation to increase market share, drive profitability and grow into an industry leader that delivers long-term shareholder value. The pillars of the company’s strategy include innovation; consumer focus; efficiency; and market expansion. History OrganiGram Holdings Inc. was incorporated in 2010.